BRPI0921569A2 - anticorpos para il-6 e uso dos mesmos - Google Patents

anticorpos para il-6 e uso dos mesmos

Info

Publication number: BRPI0921569A2
Authority: BR; Brazil
Prior art keywords: antibodies
Prior art date: 2008-11-25

Application number

BRPI0921569A

Other languages

English (en)

Inventor

Elisabeth Carvalho-Jensen Anne

Dutzar Ben

Kovacevich Brian

T L Smith Jeffrey

Latham John

Olson Katie

Garcia-Martinez Leon

Litton Mark

Schatzman Randall

Original Assignee

Alder Biopharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-25

Filing date

2009-11-24

Publication date

2019-09-24

2009-02-05 Priority claimed from US12/366,567 external-priority patent/US8062864B2/en

2009-02-24 Priority claimed from US12/391,717 external-priority patent/US8178101B2/en

2009-03-06 Priority claimed from US12/399,156 external-priority patent/US20090238825A1/en

2009-07-14 Priority claimed from US12/502,581 external-priority patent/US8323649B2/en

2009-11-24 Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc

2019-09-24 Publication of BRPI0921569A2 publication Critical patent/BRPI0921569A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Virology (AREA)
Hematology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)

BRPI0921569A 2008-11-25 2009-11-24 anticorpos para il-6 e uso dos mesmos BRPI0921569A2 (pt)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US11783908P	2008-11-25	2008-11-25
US11786108P	2008-11-25	2008-11-25
US11781108P	2008-11-25	2008-11-25
US12/366,567 US8062864B2 (en)	2007-05-21	2009-02-05	Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US39161509A	2009-02-24	2009-02-24
US12/391,717 US8178101B2 (en)	2007-05-21	2009-02-24	Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US12/399,156 US20090238825A1 (en)	2007-05-21	2009-03-06	Novel rabbit antibody humanization methods and humanized rabbit antibodies
US12/502,581 US8323649B2 (en)	2008-11-25	2009-07-14	Antibodies to IL-6 and use thereof
PCT/US2009/006274 WO2010065079A2 (en)	2008-11-25	2009-11-24	Antibodies to il-6 and use thereof

Publications (1)

Publication Number	Publication Date
BRPI0921569A2 true BRPI0921569A2 (pt)	2019-09-24

Family

ID=42233511

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0921569A BRPI0921569A2 (pt)	2008-11-25	2009-11-24	anticorpos para il-6 e uso dos mesmos

Country Status (19)

Country	Link
EP (5)	EP2361095B1 (pt)
JP (9)	JP5832291B2 (pt)
KR (4)	KR20110112307A (pt)
CN (5)	CN102292107B (pt)
AR (1)	AR074227A1 (pt)
AU (5)	AU2009323008B2 (pt)
BR (1)	BRPI0921569A2 (pt)
CA (1)	CA2744400C (pt)
DK (1)	DK3338799T3 (pt)
EA (1)	EA201100641A1 (pt)
HK (1)	HK1256622A1 (pt)
IL (2)	IL212728B (pt)
MX (7)	MX2011005408A (pt)
NO (1)	NO2367570T3 (pt)
NZ (2)	NZ602166A (pt)
SG (1)	SG171804A1 (pt)
TW (6)	TWI469793B (pt)
WO (4)	WO2010065079A2 (pt)
ZA (1)	ZA201103803B (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2892925T3 (es)	2006-03-31	2022-02-07	Chugai Pharmaceutical Co Ltd	Métodos para controlar la farmacocinética en sangre de anticuerpos
HUE032563T2 (en)	2007-05-21	2017-09-28	Alderbio Holdings Llc	Antibodies to IL-6 and their use
US8404235B2 (en)	2007-05-21	2013-03-26	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en)	2007-05-21	2012-05-15	Alderbio Holdings Inc.	Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8252286B2 (en)	2007-05-21	2012-08-28	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en)	2007-05-21	2011-11-22	Alderbio Holdings Llc	Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en)	2007-05-21	2017-07-11	Alderbio Holdings Llc	Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US7906117B2 (en)	2007-05-21	2011-03-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
AU2008304748C1 (en)	2007-09-26	2014-06-12	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
KR102057826B1 (ko)	2008-04-11	2019-12-20	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
US8323649B2 (en)	2008-11-25	2012-12-04	Alderbio Holdings Llc	Antibodies to IL-6 and use thereof
CA2744400C (en) *	2008-11-25	2019-01-15	Alder Biopharmaceuticals, Inc.	Antibodies to il-6 and use thereof
US9212223B2 (en)	2008-11-25	2015-12-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en)	2008-11-25	2012-12-25	Alderbio Holdings Llc	Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en)	2008-11-25	2013-04-16	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en)	2008-11-25	2016-09-27	Alderbio Holdings Llc	Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en)	2008-11-25	2015-03-31	Alderbio Holdings Llc	Anti-IL-6 antibodies for the treatment of arthritis
US7947653B1 (en)	2009-10-09	2011-05-24	Cold Spring Harbor Laboratory	Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en)	2009-10-09	2012-12-04	Cold Spring Harbor Laboratory	Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
US9775921B2 (en)	2009-11-24	2017-10-03	Alderbio Holdings Llc	Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066374A2 (en)	2009-11-24	2011-06-03	Alder Biopharmaceuticals, Inc.	Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
JP2012041271A (ja) *	2010-08-12	2012-03-01	Univ Of Tokyo	血栓形成を抑制する作用を有する組成物
TWI603738B (zh)	2010-11-08	2017-11-01	建南德克公司	皮下投予抗－ｉｌ－６受體抗體
US9304134B2 (en)	2010-11-23	2016-04-05	Alderbio Holdings Llc	Anti-IL-6 antibodies for the treatment of anemia
TWI812066B (zh)	2010-11-30	2023-08-11	日商中外製藥股份有限公司	具有鈣依存性的抗原結合能力之抗體
JP5818906B2 (ja) *	2011-10-12	2015-11-18	Ｓｂｉファーマ株式会社	抗ガン剤の副作用の予防剤及び／又は治療剤
JO3370B1 (ar)	2011-11-10	2019-03-13	Regeneron Pharma	طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
EP4039275A1 (en) *	2012-05-03	2022-08-10	Boehringer Ingelheim International GmbH	Anti-il-23p19 antibodies
LT4461308T (lt) *	2012-07-13	2025-06-10	The Trustees Of The University Of Pennsylvania	Car priešnavikinio aktyvumo toksiškumo valdymas
EP2875360B1 (en) *	2012-07-20	2018-08-08	Agency For Science, Technology And Research	In vitro assay for predicting renal proximal tubular cell toxicity
WO2014042251A1 (ja) *	2012-09-13	2014-03-20	中外製薬株式会社	遺伝子ノックイン非ヒト動物
KR102321372B1 (ko) *	2012-10-22	2021-11-11	원니스 바이오테크 컴퍼니 리미티드	인터류킨-6에 대한 항체 및 그의 용도
PT2956476T (pt) *	2013-02-18	2020-02-21	Vegenics Pty Ltd	Moléculas de ligação e usos destas
KR101332836B1 (ko) *	2013-05-15	2013-11-27	재단법인 통합의료진흥원	자음강화탕을 포함하는 유방암 치료용 조성물
EP3009518B1 (en)	2013-06-11	2020-08-12	National Center of Neurology and Psychiatry	Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
WO2015054293A1 (en) *	2013-10-07	2015-04-16	Alder Biopharmaceuticals, Inc.	Anti-il-6 antibodies for the treatment of psoriatic arthritis
CN103739672B (zh) *	2013-12-31	2015-06-10	威特曼生物科技（南京）有限公司	一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用
EP2926815A1 (en)	2014-04-03	2015-10-07	Institut Curie	New derivatives of cephalosporin for treating cancer
JO3663B1 (ar) *	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN104147120A (zh) *	2014-09-04	2014-11-19	成都市飞龙水处理技术研究所	一种治疗多发性神经纤维瘤的内服中药液及其制备方法
CN107074976B (zh) *	2014-11-04	2020-10-09	北京韩美药品有限公司	同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
JP6130983B2 (ja)	2015-02-27	2017-05-17	中外製薬株式会社	Ｉｌ−６関連疾患治療用組成物
JP6875683B2 (ja)	2015-05-19	2021-05-26	国立研究開発法人国立精神・神経医療研究センター	多発性硬化症（ｍｓ）患者の新規治療適用判断方法
JP7128460B2 (ja)	2015-06-04	2022-08-31	国立研究開発法人国立精神・神経医療研究センター	Ｉｌ－６阻害剤を有効成分とする精神疾患治療剤
CN108026582A (zh) *	2015-07-31	2018-05-11	米迪缪尼有限公司	用于治疗海帕西啶介导的病症的方法
CN105586426B (zh) *	2016-03-01	2019-02-26	浙江大学	与慢性乙型肝炎病毒感染相关的IL-6基因rs2069852位点标志物及其应用
KR102055390B1 (ko) *	2017-01-06	2019-12-12	경북대학교 산학협력단	혈전-표적성 펩타이드, 페리틴 단편 및 혈전 용해성 펩타이드를 포함하는 융합 펩타이드 및 이의 용도
KR20200012823A (ko)	2017-02-01	2020-02-05	예일 유니버시티	이뇨제 내성의 치료
EP3620531A4 (en)	2017-05-02	2021-03-17	National Center of Neurology and Psychiatry	METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
AU2017429312B2 (en) *	2017-08-31	2022-03-24	Hanyi Bio-Technology Company Ltd.	Uses of cannabidiol in preparation of drugs for resisting against influenza
EP3698808B1 (en)	2017-10-20	2025-01-01	Hyogo College Of Medicine	Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US11458178B2 (en)	2017-11-24	2022-10-04	Riken	Method for alleviating fatigue
CN111867627A (zh) *	2018-01-04	2020-10-30	维塔里斯股份有限公司	抗IL-6抗体例如克拉扎珠单抗(Clazakizumab)用于使实体器官移植接受者脱敏和/或用于预防、稳定或减轻抗体介导的排斥(ABMR)的用途
CA3087699A1 (en)	2018-01-05	2019-07-11	Corvidia Therapeutics, Inc.	Methods for treating il-6 mediated inflammation without immunosuppression
EP3735427A4 (en) *	2018-01-05	2021-09-15	Immunext Inc.	ANTI-MCT1 ANTIBODIES AND USES THEREOF
WO2019151418A1 (ja)	2018-01-31	2019-08-08	元一加藤	Ｉｌ－６阻害剤を含有する喘息の治療剤
WO2019164628A1 (en) *	2018-02-26	2019-08-29	The Trustees Of Columbia University In The City Of New York	Zinc associated treatment for and diagnosis of cachexia
US11633399B2 (en)	2018-12-25	2023-04-25	Sol-Gel Technologies Ltd.	Treatment of skin disorders with compositions comprising an EGFR inhibitor
CN110297093B (zh) *	2019-03-18	2022-04-22	山西瑞豪生物科技有限公司	一种检测人免疫球蛋白g4的方法和试剂盒
IL287220B2 (en)	2019-04-17	2026-03-01	Univ Hiroshima	A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
CN114761013A (zh)	2019-09-27	2022-07-15	迪斯克医药公司	治疗骨髓纤维化和相关病症的方法
MX2022005375A (es)	2019-11-05	2022-10-07	Abbvie Inc	Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con neoplasias mieloproliferativas (nmp) con navitoclax.
CN111053909A (zh) *	2020-02-27	2020-04-24	南通大学	2019-nCoV3CL水解酶抑制剂与IL-6单抗在制备治疗新冠肺炎药物中的应用
EP4121455A1 (en) *	2020-03-18	2023-01-25	Vitaeris Inc.	Use of anti-il-6 antibody, e.g., clazakizumab for treatment/prevention of ards associated with coronavirus (covid-19) infection
US20230151107A1 (en) *	2020-04-04	2023-05-18	Biocon Limited	Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
WO2021231798A1 (en)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN112098549B (zh) *	2020-09-03	2022-11-15	长沙创新药物工业技术研究院有限公司	一种测定盐酸阿比多尔溶液中杂质含量的方法
CN112175080B (zh) *	2020-10-22	2021-05-25	优睿赛思(武汉)生物科技有限公司	抗人白介素-6高亲和力兔单克隆抗体及应用
WO2022091375A1 (ja)	2020-10-30	2022-05-05	国立研究開発法人国立循環器病研究センター	周産期心筋症治療剤
WO2022188013A1 (zh) *	2021-03-08	2022-09-15	苏州大学	化学发光介导的纳米颗粒、自组装聚集体及其制备方法和应用
TW202311743A (zh) *	2021-07-26	2023-03-16	日商電化股份有限公司	包含人類化抗體之試劑
EP4501336A4 (en) *	2022-03-24	2025-10-15	Therabest Co Ltd	Pharmaceutical composition for the prevention or treatment of degenerative brain diseases with natural killer cells

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5202422A (en)	1989-10-27	1993-04-13	The Scripps Research Institute	Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5210075A (en)	1990-02-16	1993-05-11	Tanabe Seiyaku Co., Ltd.	Interleukin 6 antagonist peptides
EP0542810A1 (en)	1990-08-02	1993-05-26	B.R. Centre Limited	Methods for the production of proteins with a desired function
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
EP1400536A1 (en)	1991-06-14	2004-03-24	Genentech Inc.	Method for making humanized antibodies
WO1994021293A1 (en)	1993-03-19	1994-09-29	Duke University	Method of treatment of tumors with an antibody binding to tenascin
US5856135A (en)	1993-05-31	1999-01-05	Chugai Seiyaku Kabushiki Kaisha	Reshaped human antibody to human interleukin-6
EP0702516A4 (en)	1993-06-01	1998-04-22	Life Technologies Inc	GENETIC IMMUNIZATION WITH CATIONIC LIPIDS
ES2251723T3 (es)	1994-08-12	2006-05-01	Immunomedics, Inc.	Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
DE69637845D1 (de)	1995-09-28	2009-04-09	Yeda Res & Dev	Synthetische peptide mit il-6 aktivitäthemmung
US6841533B1 (en)	1995-12-07	2005-01-11	Peptor Limited	Conformationally constrained backbone cyclized interleukin-6 antagonists
US6653104B2 (en)	1996-10-17	2003-11-25	Immunomedics, Inc.	Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
AU1979599A (en) *	1998-01-14	1999-08-02	Chiron S.P.A.	(neisseria meningitidis) antigens
EP0972780A1 (en)	1998-05-18	2000-01-19	Applied Research Systems ARS Holding N.V.	Il-6 antagonist peptides
US7345217B2 (en) *	1998-09-22	2008-03-18	Mendel Biotechnology, Inc.	Polynucleotides and polypeptides in plants
IL139380A0 (en) *	2000-10-31	2001-11-25	Prochon Biotech Ltd	Active variants of fibroblast growth factor
US20040198661A1 (en) *	2000-12-08	2004-10-07	Bowdish Katherine S.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7169573B2 (en) *	2001-02-20	2007-01-30	Oklahoma Medical Research Foundation	Method for monitoring coagulability and hypercoagulable states
JP2003066047A (ja) *	2001-06-14	2003-03-05	Matsushita Electric Ind Co Ltd	免疫反応測定方法及びそれに用いる免疫反応測定用試薬
US20030219839A1 (en) *	2001-09-20	2003-11-27	Katherine Bowdish	Anti-PDGF antibodies and methods for producing engineered antibodies
BRPI0214168B8 (pt) *	2001-11-14	2021-05-25	Centocor Inc	anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
KR100468316B1 (ko)	2002-01-29	2005-01-27	주식회사 웰진	Ｄｎａ의 세포 또는 조직 내 전달 효율을 높이는 펩타이드
AU2003264009A1 (en) *	2002-08-15	2004-03-03	Epitomics, Inc.	Humanized rabbit antibodies
JP4463104B2 (ja)	2002-08-30	2010-05-12	財団法人化学及血清療法研究所	ヒト抗ヒトインターロイキン−６抗体及び該抗体フラグメント
US20050090453A1 (en)	2003-01-15	2005-04-28	Solbec Pharmaceuticals Co., Ltd.	Methods of modulating IL-6
WO2004101529A1 (ja)	2003-05-19	2004-11-25	Ono Pharmaceutical Co., Ltd.	含窒素複素環化合物およびその医薬用途
KR101193708B1 (ko) *	2003-10-17	2012-10-22	추가이 세이야쿠 가부시키가이샤	중피종 치료제
PT1678314E (pt)	2003-10-22	2012-11-27	Keck Graduate Inst	Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide
BRPI0512915A (pt) *	2004-06-29	2008-04-15	Warner Lambert Co	terapias de combinação utilizando inibidores benzamida do receptor p2x7
GB0419424D0 (en)	2004-09-02	2004-10-06	Viragen Scotland Ltd	Transgene optimisation
US20060121042A1 (en) *	2004-10-27	2006-06-08	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20080033027A1 (en) *	2005-03-21	2008-02-07	Vicus Therapeutics Spe 1, Llc	Drug combination pharmaceutical compositions and methods for using them
US7431927B2 (en) *	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
PE20061324A1 (es) *	2005-04-29	2007-01-15	Centocor Inc	Anticuerpos anti-il-6, composiciones, metodos y usos
EP2336181A1 (en)	2005-12-09	2011-06-22	UCB Pharma, S.A.	Antibody molecules having specificity for human IL-6
WO2008093148A2 (en) *	2005-12-22	2008-08-07	Anaborex, Inc.	Compositions and methods for prevention and treatment of cachexia
WO2007076927A1 (en) *	2005-12-30	2007-07-12	Merck Patent Gmbh	Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
US9399061B2 (en) *	2006-04-10	2016-07-26	Abbvie Biotechnology Ltd	Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
DK2021463T3 (en) *	2006-05-19	2017-01-16	Alder Biopharmaceuticals Inc	Culture method to obtain a cloned population of antigen-specific B cells
JP2009536641A (ja) *	2006-05-31	2009-10-15	ハンワケミカルコーポレイション	Ｖｃａｍ−１特異的モノクローナル抗体
MX2009001110A (es) *	2006-08-03	2009-05-11	Vaccinex Inc	Anticuerpos monoclonales anti-il-6 y usos de los mismos.
WO2008042611A2 (en)	2006-09-29	2008-04-10	Centocor, Inc.	Method of using il6 antagonists with mitoxantrone for prostate cancer
TW200831528A (en) *	2006-11-30	2008-08-01	Astrazeneca Ab	Compounds
US8178101B2 (en)	2007-05-21	2012-05-15	Alderbio Holdings Inc.	Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
KR20170036814A (ko) *	2007-05-21	2017-04-03	앨더바이오 홀딩스 엘엘씨	신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US8062864B2 (en)	2007-05-21	2011-11-22	Alderbio Holdings Llc	Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
HUE032563T2 (en) *	2007-05-21	2017-09-28	Alderbio Holdings Llc	Antibodies to IL-6 and their use
CA2744400C (en) *	2008-11-25	2019-01-15	Alder Biopharmaceuticals, Inc.	Antibodies to il-6 and use thereof
US11783908B2 (en)	2019-10-11	2023-10-10	SK Hynix Inc.	Stacked semiconductor device and semiconductor system including the same

2009
- 2009-11-24 CA CA2744400A patent/CA2744400C/en active Active
- 2009-11-24 MX MX2011005408A patent/MX2011005408A/es active IP Right Grant
- 2009-11-24 AU AU2009323008A patent/AU2009323008B2/en not_active Ceased
- 2009-11-24 AU AU2009323007A patent/AU2009323007B2/en not_active Ceased
- 2009-11-24 EP EP09830692.1A patent/EP2361095B1/en not_active Not-in-force
- 2009-11-24 KR KR1020117014629A patent/KR20110112307A/ko not_active Ceased
- 2009-11-24 MX MX2011005396A patent/MX2011005396A/es active IP Right Grant
- 2009-11-24 MX MX2014008792A patent/MX364874B/es unknown
- 2009-11-24 JP JP2011537433A patent/JP5832291B2/ja not_active Expired - Fee Related
- 2009-11-24 WO PCT/US2009/006274 patent/WO2010065079A2/en not_active Ceased
- 2009-11-24 DK DK17194768.2T patent/DK3338799T3/da active
- 2009-11-24 CN CN200980155125.9A patent/CN102292107B/zh not_active Expired - Fee Related
- 2009-11-24 EP EP17194768.2A patent/EP3338799B1/en active Active
- 2009-11-24 AU AU2009323002A patent/AU2009323002B2/en not_active Ceased
- 2009-11-24 NO NO09830697A patent/NO2367570T3/no unknown
- 2009-11-24 CN CN200980155121.0A patent/CN102438653B/zh not_active Expired - Fee Related
- 2009-11-24 SG SG2011037496A patent/SG171804A1/en unknown
- 2009-11-24 MX MX2014004474A patent/MX365985B/es unknown
- 2009-11-24 CN CN200980155124.4A patent/CN102292449B/zh not_active Expired - Fee Related
- 2009-11-24 JP JP2011537437A patent/JP5898496B2/ja active Active
- 2009-11-24 MX MX2011005411A patent/MX2011005411A/es active IP Right Grant
- 2009-11-24 AU AU2009323009A patent/AU2009323009B2/en not_active Ceased
- 2009-11-24 NZ NZ602166A patent/NZ602166A/en not_active IP Right Cessation
- 2009-11-24 KR KR1020117014634A patent/KR20110091780A/ko not_active Ceased
- 2009-11-24 EA EA201100641A patent/EA201100641A1/ru unknown
- 2009-11-24 WO PCT/US2009/006266 patent/WO2010065077A2/en not_active Ceased
- 2009-11-24 JP JP2011537432A patent/JP5620918B2/ja not_active Expired - Fee Related
- 2009-11-24 CN CN201410058493.4A patent/CN103861106B/zh active Active
- 2009-11-24 BR BRPI0921569A patent/BRPI0921569A2/pt not_active IP Right Cessation
- 2009-11-24 JP JP2011537436A patent/JP5832292B2/ja not_active Expired - Fee Related
- 2009-11-24 KR KR1020117014636A patent/KR20110091781A/ko not_active Ceased
- 2009-11-24 EP EP09830696.2A patent/EP2361096B1/en not_active Not-in-force
- 2009-11-24 WO PCT/US2009/006257 patent/WO2010065072A1/en not_active Ceased
- 2009-11-24 NZ NZ592516A patent/NZ592516A/xx not_active IP Right Cessation
- 2009-11-24 WO PCT/US2009/006273 patent/WO2010065078A1/en not_active Ceased
- 2009-11-24 EP EP09830697.0A patent/EP2367570B1/en active Active
- 2009-11-24 EP EP09830695.4A patent/EP2376126B1/en not_active Not-in-force
- 2009-11-24 CN CN200980155120.6A patent/CN102292106B/zh active Active
- 2009-11-24 KR KR1020117014632A patent/KR20110112308A/ko not_active Ceased
- 2009-11-25 TW TW98140118A patent/TWI469793B/zh not_active IP Right Cessation
- 2009-11-25 TW TW098140115A patent/TWI481413B/zh not_active IP Right Cessation
- 2009-11-25 TW TW103136468A patent/TWI547502B/zh not_active IP Right Cessation
- 2009-11-25 AR ARP090104558A patent/AR074227A1/es unknown
- 2009-11-25 TW TW104119976A patent/TWI617318B/zh not_active IP Right Cessation
- 2009-11-25 TW TW098140116A patent/TWI533883B/zh active
- 2009-11-25 TW TW098140117A patent/TWI498120B/zh not_active IP Right Cessation
2011
- 2011-05-05 IL IL212728A patent/IL212728B/en active IP Right Grant
- 2011-05-20 MX MX2019005415A patent/MX2019005415A/es unknown
- 2011-05-20 MX MX2019007500A patent/MX2019007500A/es unknown
- 2011-05-24 ZA ZA2011/03803A patent/ZA201103803B/en unknown
2014
- 2014-09-18 JP JP2014189695A patent/JP5815098B2/ja not_active Expired - Fee Related
2015
- 2015-05-22 JP JP2015104877A patent/JP6035373B2/ja active Active
- 2015-05-26 JP JP2015106107A patent/JP6050431B2/ja not_active Expired - Fee Related
- 2015-05-26 JP JP2015106045A patent/JP6050430B2/ja active Active
2016
- 2016-10-31 JP JP2016213750A patent/JP6190028B2/ja not_active Expired - Fee Related
- 2016-11-11 AU AU2016256810A patent/AU2016256810B2/en not_active Ceased
2018
- 2018-02-01 IL IL257290A patent/IL257290A/en unknown
- 2018-12-10 HK HK18115754.4A patent/HK1256622A1/en unknown

Also Published As

Publication number	Publication date
EP2376126A4 (en)	2013-07-24
EA201100641A1 (ru)	2012-01-30
WO2010065077A2 (en)	2010-06-10
EP2361096A1 (en)	2011-08-31
JP2012509873A (ja)	2012-04-26
EP2367570A4 (en)	2013-07-31
EP2361096A4 (en)	2013-01-09
EP3338799A1 (en)	2018-06-27
JP6190028B2 (ja)	2017-08-30
JP2015028048A (ja)	2015-02-12
TW201023888A (en)	2010-07-01
KR20110091781A (ko)	2011-08-12
WO2010065079A3 (en)	2010-07-29
IL257290A (en)	2018-03-29
AU2009323008B2 (en)	2016-02-18
EP2361095B1 (en)	2017-12-20
JP2015187132A (ja)	2015-10-29
TWI469793B (zh)	2015-01-21
AR074227A1 (es)	2010-12-29
TW201023890A (en)	2010-07-01
EP2367570A2 (en)	2011-09-28
JP5620918B2 (ja)	2014-11-05
NO2367570T3 (pt)	2018-05-19
TW201527321A (zh)	2015-07-16
CN102292449A (zh)	2011-12-21
CN102292106A (zh)	2011-12-21
KR20110091780A (ko)	2011-08-12
MX2019007500A (es)	2019-09-04
IL212728A0 (en)	2011-07-31
JP2015157855A (ja)	2015-09-03
KR20110112308A (ko)	2011-10-12
MX2011005396A (es)	2011-06-09
TW201028164A (en)	2010-08-01
AU2009323002A1 (en)	2010-06-10
EP3338799B1 (en)	2021-04-07
TWI498120B (zh)	2015-09-01
SG171804A1 (en)	2011-07-28
ZA201103803B (en)	2022-03-30
NZ602166A (en)	2014-02-28
JP6050431B2 (ja)	2016-12-21
TW201609139A (zh)	2016-03-16
WO2010065078A1 (en)	2010-06-10
JP2012509872A (ja)	2012-04-26
EP2376126A2 (en)	2011-10-19
EP2376126B1 (en)	2017-12-20
JP6050430B2 (ja)	2016-12-21
AU2016256810B2 (en)	2019-01-17
IL212728B (en)	2018-02-28
JP2012509874A (ja)	2012-04-26
CN102292449B (zh)	2016-03-30
MX2019005415A (es)	2019-08-12
TWI481413B (zh)	2015-04-21
EP2361095A4 (en)	2013-07-24
AU2009323007A1 (en)	2010-06-10
CN103861106A (zh)	2014-06-18
TWI547502B (zh)	2016-09-01
AU2009323009A1 (en)	2010-06-10
AU2016256810A1 (en)	2016-12-01
CN102438653B (zh)	2019-04-23
MX2011005408A (es)	2011-06-16
MX2011005411A (es)	2011-06-16
TWI533883B (zh)	2016-05-21
WO2010065072A1 (en)	2010-06-10
WO2010065079A2 (en)	2010-06-10
CN103861106B (zh)	2017-03-22
JP2015164951A (ja)	2015-09-17
JP2017048222A (ja)	2017-03-09
KR20110112307A (ko)	2011-10-12
NZ592516A (en)	2013-02-22
EP2361095A1 (en)	2011-08-31
WO2010065072A8 (en)	2010-12-16
AU2009323008A1 (en)	2010-06-10
JP5898496B2 (ja)	2016-04-06
JP6035373B2 (ja)	2016-11-30
CN102438653A (zh)	2012-05-02
CN102292107B (zh)	2014-03-26
MX365985B (es)	2019-06-21
EP2367570B1 (en)	2017-12-20
HK1256622A1 (en)	2019-09-27
AU2009323009B2 (en)	2016-01-28
AU2009323007B2 (en)	2016-01-28
JP5832291B2 (ja)	2015-12-16
EP2361096B1 (en)	2019-01-02
CA2744400C (en)	2019-01-15
CN102292106B (zh)	2016-02-03
WO2010065077A3 (en)	2010-09-10
JP5815098B2 (ja)	2015-11-17
TWI617318B (zh)	2018-03-11
CA2744400A1 (en)	2010-06-10
AU2009323002B2 (en)	2016-01-28
MX364874B (es)	2019-05-09
TW201023889A (en)	2010-07-01
JP2012509871A (ja)	2012-04-26
JP5832292B2 (ja)	2015-12-16
CN102292107A (zh)	2011-12-21
DK3338799T3 (da)	2021-06-14

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0921569A2 (pt)	2019-09-24	anticorpos para il-6 e uso dos mesmos
IL288203A (en)	2022-01-01	Meditopes and meditope-binding antibodies and uses thereof
BRPI1014544A8 (pt)	2016-10-11	anticorpos anti-il-17f e metodos de uso dos mesmos
BRPI0906478A2 (pt)	2015-11-24	anticorpo anti-nr10 e uso do mesmo
PT2427212T (pt)	2017-11-20	Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI0914007A2 (pt)	2015-11-17	anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos
BRPI0915928A2 (pt)	2015-11-03	composições e métodos de uso para anticorpos terapêuticos
BRPI0912198A2 (pt)	2019-09-24	anticorpos anti-fn14 e usos dos mesmos
BRPI0819909A2 (pt)	2017-12-19	anticorpos antimesotelina e usos dos mesmos
BR112013013781A2 (pt)	2016-09-13	anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
BRPI0914943A2 (pt)	2013-09-17	anticorpos de il-6 e sua utilizaÇço
BRPI0911297A2 (pt)	2019-09-24	composição e métodos para preparo e uso das mesmas
BRPI0907453A2 (pt)	2015-07-14	Compostos, uso e preparação dos mesmos
BRPI0913656A2 (pt)	2019-09-24	anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
BRPI0821110A2 (pt)	2015-07-07	Anticorpo anti nr-10 e uso do mesmo
BRPI1009455A2 (pt)	2016-03-01	anticorpos anti-c40 e usos dos mesmos
DOP2010000260A (es)	2010-10-15	Derivado heterociclico fusionado y su uso
BR112014012590A2 (pt)	2017-06-20	anticorpos anti-cd98 e métodos de uso dos mesmos
BRPI0921433A2 (pt)	2017-06-06	uso de anticorpos anti-cs1 para o tratamento de linfomas raros
BRPI1012533A2 (pt)	2015-09-22	composto de piradazinona e uso do mesmo
BRPI1009413A2 (pt)	2016-03-01	emulsões e adesivos contendo proteína e produção e uso dos mesmos
BRPI1010024A2 (pt)	2019-09-24	derivados de aminopirrolidinona e uso dos mesmos
BRPI0921320A2 (pt)	2018-05-22	composições de anticorpo estáveis e métodos para estabilizar os mesmos
BR112012003661A2 (pt)	2017-04-25	"compostos de biarila e métodos de uso dos mesmos."
UY33132A (es)	2011-07-29	Proteínas solubles para su uso terapéutico